Soluble RAGE but Not Endogenous Secretory RAGE is Associated with Albuminuria in Patients with Type 2 Diabetes

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2007 Mar 9

PMID 17343760

Citations 40

Authors

Per M Humpert

Zdenka Djuric

Stefan Kopf

Gottfried Rudofsky

Michael Morcos

Peter P Nawroth

Angelika Bierhaus

Affiliations

Soon will be listed here.

Abstract

Background: Total circulating soluble receptor for advanced glycation endproducts (sRAGE) and a more defined endogenous secretory splice variant of the receptor (esRAGE) were shown to be associated with different markers of cardiovascular risk in patients with diabetes. Since previous data were partly divergent, the aim of this study was to compare sRAGE and esRAGE in a head-to-head analysis in patients with type 2 diabetes (T2DM) with albuminuria.

Methods: sRAGE and esRAGE were studied in plasma of 110 T2DM patients using enzyme-linked immunosorbant assays (ELISA) detecting either sRAGE or esRAGE only. Both sRAGE and esRAGE were compared with regard to applicability as markers for vascular disease and glucose control in T2DM.

Results: In bivariate analysis, sRAGE correlated with age (R = 0.22, p = 0.02) and the 24 hour albumin excretion rate (R = 0.18, p = 0.05), while esRAGE correlated positively with age only (R = 0.23, p = 0.02). In contrast to previous reports, neither sRAGE nor esRAGE correlated with glucose control or intima-media-thickness (IMT) as a predictor of macrovascular disease. In multivariate regression models, the associations between sRAGE and albuminuria as well as esRAGE and age were shown to be independent of glucose control, diabetes duration, body-mass index, glomerular filtration rate, blood pressure and gender.

Conclusion: This is the first study comparing sRAGE and esRAGE as markers of vascular complications in patients with T2DM. sRAGE but not esRAGE is independently associated with albuminuria in these patients while neither sRAGE nor esRAGE are associated with markers of glucose control or macrovascular disease.

Citing Articles

Understanding the effects of COVID-19 on patients with diabetic nephropathy: a systematic review.

Altoukhi S, Zamkah M, Alharbi R, Alghamdi S, Aldawsari L, Tarabulsi M Ann Med Surg (Lond). 2024; 86(6):3478-3486.

PMID: 38846830 PMC: 11152851. DOI: 10.1097/MS9.0000000000002053.

An update on the interaction between COVID-19, vaccines, and diabetic kidney disease.

Yang Y, Zou S, Xu G Front Immunol. 2022; 13:999534.

PMID: 36341356 PMC: 9630353. DOI: 10.3389/fimmu.2022.999534.

Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.

Sabbatinelli J, Castiglione S, Macri F, Giuliani A, Ramini D, Vinci M Cardiovasc Diabetol. 2022; 21(1):95.

PMID: 35668468 PMC: 9169316. DOI: 10.1186/s12933-022-01535-3.

Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.

Sourris K, Watson A, Jandeleit-Dahm K Handb Exp Pharmacol. 2020; 264:395-423.

PMID: 32809100 DOI: 10.1007/164_2020_391.

Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease.

Patel D, Bose M, Cooper M Int J Mol Sci. 2020; 21(6).

PMID: 32210089 PMC: 7139394. DOI: 10.3390/ijms21062218.

References

Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux J . Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem. 2005; 51(9):1749-50. DOI: 10.1373/clinchem.2005.051961. View

Katakami N, Matsuhisa M, Kaneto H, Matsuoka T, Sakamoto K, Nakatani Y . Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care. 2005; 28(11):2716-21. DOI: 10.2337/diacare.28.11.2716. View

Forbes J, Thorpe S, Thallas-Bonke V, Pete J, Thomas M, Deemer E . Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol. 2005; 16(8):2363-72. DOI: 10.1681/ASN.2005010062. View

Hudson B, Harja E, Moser B, Schmidt A . Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler Thromb Vasc Biol. 2005; 25(5):879-82. DOI: 10.1161/01.ATV.0000164804.05324.8b. View

Falcone C, Emanuele E, DAngelo A, Buzzi M, Belvito C, Cuccia M . Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005; 25(5):1032-7. DOI: 10.1161/01.ATV.0000160342.20342.00. View

Hanford L, Enghild J, Valnickova Z, Petersen S, Schaefer L, Schaefer T . Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem. 2004; 279(48):50019-24. PMC: 1868562. DOI: 10.1074/jbc.M409782200. View

Ebihara I, Nakamura T, Shimada N, Koide H . Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1998; 32(4):544-50. DOI: 10.1016/s0272-6386(98)70015-0. View

Frye E, Degenhardt T, Thorpe S, Baynes J . Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem. 1998; 273(30):18714-9. DOI: 10.1074/jbc.273.30.18714. View

Bierhaus A, Hofmann M, Ziegler R, Nawroth P . AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res. 1998; 37(3):586-600. DOI: 10.1016/s0008-6363(97)00233-2. View

10.

Monnier V, Sell D, Nagaraj R, Miyata S, Grandhee S, Odetti P . Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes. 1992; 41 Suppl 2:36-41. DOI: 10.2337/diab.41.2.s36. View

11.

Sampson M, Drury P . Accurate estimation of glomerular filtration rate in diabetic nephropathy from age, body weight, and serum creatinine. Diabetes Care. 1992; 15(5):609-12. DOI: 10.2337/diacare.15.5.609. View

12.

Yonekura H, Yamamoto Y, Sakurai S, Petrova R, Abedin M, Li H . Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2002; 370(Pt 3):1097-109. PMC: 1223244. DOI: 10.1042/BJ20021371. View

13.

Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert P, Chen J . Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001; 50(12):2792-808. DOI: 10.2337/diabetes.50.12.2792. View

14.

Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S . N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999; 274(44):31740-9. DOI: 10.1074/jbc.274.44.31740. View

15.

Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A . Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther. 2005; 7(4):R817-24. PMC: 1175032. DOI: 10.1186/ar1749. View

16.

Pullerits R, Brisslert M, Jonsson I, Tarkowski A . Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum. 2006; 54(12):3898-907. DOI: 10.1002/art.22217. View

17.

Koyama H, Shoji T, Fukumoto S, Shinohara K, Shoji T, Emoto M . Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol. 2006; 27(1):147-53. DOI: 10.1161/01.ATV.0000251502.88818.4b. View

18.

Basta G, Sironi A, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A . Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 2006; 91(11):4628-34. DOI: 10.1210/jc.2005-2559. View

19.

Tan K, Shiu S, Chow W, Leng L, Bucala R, Betteridge D . Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia. 2006; 49(11):2756-62. DOI: 10.1007/s00125-006-0394-1. View

20.

Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata K, Hui L . Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract. 2006; 73(2):158-65. DOI: 10.1016/j.diabres.2005.12.013. View